This NICE guideline provides recommendations for non-specialists for the identification and referral guidance for children and adults who present with symptoms or risk factors of acute kidney injury.
This NICE pathway provides an interactive flowchart of myeloma diagnosis and management using information from both NICE and other sources.
This NICE pathway provides an interactive flowchart of myeloma diagnosis and management using information from both NICE and other sources.
Some drugs used for the treatment of myeloma can increase the risk of venous thromboembolic events. This NICE guidelines outlines how healthcare professionals can manage patients who may be at higher risk of developing VTE in hospital.
This interactive flowchart developed by NICE gives an overview of blood and bone cancer diagnosis, management and treatment as well as NHS service organisation recommendations.
The haematological malignancies patient report outcomes (HM-PRO) measure has been developed to support patients and their clinicians in discussing, addressing and better recording quality of life issues that matter patients.
Access the questionnaire here.
The IMWG present recommendations on imaging both in clinical practice and in the trial setting to help standardise the best imaging methods to use as myeloma patients progress through different disease stages.
The UK Myeloma Forum (UKMF) is a collaborative organisation of healthcare professionals and scientists which aims to improve the treatment of patients with myeloma. The annual UKMF Scientific Workshop is an all-day event where leading experts share the latest biomedical research aiming to improve understanding of myeloma and develop new strategies to improve patient outcomes. This year’s…
Myeloma is a relapsing-remitting blood cancer arising from the clonal expansion of abnormal plasma cells in the bone marrow. It is a difficult cancer to diagnose due to the vagueness of symptoms and rarity of the disease. This means myeloma patients experience some of the longest delays in diagnosis of all cancer patients. Myeloma UK…
This new treatment combination is being made available via the CDF on the NHS for the first time following a recommendation by the National Institute of Health and Care Excellence (NICE). This decision follows an earlier draft negative decision by NICE in July last year. Daratumumab, which is produced by the pharmaceutical company Janssen, belongs to a…
